A prospective study of the clinical utility of immunocytochemistry in liquid-based cytology for pancreatic tumors

A prospective study of the clinical utility of immunocytochemistry in liquid-based cytology for pancreatic tumors - A prospective study of the clinical utility of ICC in LBC for pancreatic tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020575

Enrollment

Registered

2016-01-15

Start date

2016-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Informed consent is required from all patients or their family. 2, Patients of age =>16. 3, Patients with pancreatic tumor detected by imaging modalities

Exclusion criteria

Exclusion criteria: 1, Patients with serious complication in other organ. 2, Patients who have risk of bleeding. 3, Patients with pancreatic tumor which we cannot detect or puncture by EUS. 4, Patients with performance status 4. 5, Inappropriate patients for entry on this study in the judgement of the investigator.

Design outcomes

Primary

Measure	Time frame
The diagnostic accuracy of immunocytochemistry in liquid-based cytology for pancreatic tumors	—

Countries

Japan

Contacts

Public ContactYutaka Akimoto

Okayama University Hospital Department of Gastroenterology & Hepatology

qttsp974@gmail.com086-235-7219

Outcome results